Watch TELA. Know when insiders buy.
One email the day a filing lands. Free.
TELA
TELA Bio, Inc.
1.18
+0.09 +8.26%
USD · Sep 17, 08:20 a.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · insiders 59, shorts 20
Insiders, 90 days
+$78K
net buying · 2 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $53MP/E —DIV YIELD —FCF YIELD -59.69%REV TTM $79.9M +6.1%NET INCOME −$41.2MNET DEBT $11M52W 0.56 – 1.62SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $19.3M | −4.5% | 72.3% | −$9.3M | −$11.3M | — | -0.20 | −$9.4M | $59K | −$9.4M | Aug 11 |
| Q1 2026 · Mar 31 | $19.1M | +2.9% | 65.7% | −$10.5M | −$12.3M | — | -0.21 | −$11.2M | $119K | −$11.3M | May 13 |
| Q4 2025 · Dec 31derived | $20.9M | +18.2% | 65.9% | −$6.6M | −$9M | — | -0.17 | −$4.9M | $91K | −$5M | Mar 25 |
| Q3 2025 · Sep 30 | $20.7M | +9.1% | 67.5% | −$7.6M | −$8.6M | — | -0.19 | −$5.7M | $211K | −$5.9M | Nov 14 |
| Q2 2025 · Jun 30 | $20.2M | +25.5% | 69.8% | −$9.1M | −$9.9M | — | -0.22 | −$7.9M | $114K | −$8M | Aug 11 |
| Q1 2025 · Mar 31 | $18.5M | +11.5% | 67.6% | −$10.5M | −$11.3M | — | -0.25 | −$9.7M | $32K | −$9.8M | May 13 |
| Q4 2024 · Dec 31derived | $17.6M | +3.8% | 63.6% | −$8.4M | −$9.2M | — | -0.17 | −$7.5M | $264K | −$7.8M | Mar 25 |
| Q3 2024 · Sep 30 | $19M | +25.9% | 67.8% | −$9.4M | −$10.4M | — | -0.42 | −$9M | $122K | −$9.1M | Nov 14 |
| Q2 2024 · Jun 30 | $16.1M | — | 68.8% | −$11.6M | −$12.6M | — | -0.51 | −$10.7M | $299K | −$11M | Aug 11 |
| Q1 2024 · Mar 31 | $16.6M | — | 68.3% | −$4.8M | −$5.7M | — | -0.23 | −$14.4M | $304K | −$14.7M | May 8 |
| Q4 2023 · Dec 31derived | $17M | — | 68.4% | −$12.3M | −$12.9M | — | -0.53 | −$11.1M | $205K | −$11.3M | Mar 25 |
| Q3 2023 · Sep 30 | $15.1M | — | 69.0% | −$10.2M | −$11M | — | -0.45 | −$7M | $134K | −$7.1M | Nov 8 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $80.3M | 67.7% | −$33.8M | −$38.8M | -48.4% | -0.83 | −$28.2M | $448K | −$28.7M | — | — |
| FY2024 · to Dec 31 | $69.3M | 67.1% | −$34.1M | −$37.8M | -54.6% | -1.33 | −$41.6M | $989K | −$42.6M | — | — |
| FY2023 · to Dec 31 | $58.5M | 68.6% | −$44.1M | −$46.7M | -79.8% | -2.04 | −$40.9M | $611K | −$41.5M | — | — |
| FY2022 · to Dec 31 | $41.4M | 65.3% | −$39M | −$44.3M | -106.9% | -2.72 | −$40.7M | $872K | −$41.6M | — | — |
| FY2021 · to Dec 31 | $29.5M | 63.9% | −$29.5M | −$33.3M | -112.9% | -2.30 | −$30.4M | $627K | −$31.1M | — | — |
| FY2020 · to Dec 31 | $18.2M | 61.7% | −$25.3M | −$28.8M | -158.1% | -2.23 | −$24.5M | $167K | −$24.6M | — | — |
Every number comes from TELA Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.